Effect of the histone deacetylase inhibitor depsipeptide on B-cell differentiation in both TEL-AML1-positive and negative childhood acute lymphoblastic leukemia

Haematologica

Volumn 90, Issue 12, 2005, Pages 1697-1699

  Stams, Wendy A G ^a   Den Boer, Monique L ^a   Beverloo, H Berna ^b   Kazemier, Karin M ^a   Van Wering, Elisabeth R ^c   Janka Schaub, Gritta E ^d   Pieters, Rob ^a,c  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Acute lymphoblastic leukemia; Depsipeptide; FK228; FR901228; Histone deacetylase inhibitor; TEL AML1

Indexed keywords

ASPARAGINASE; BUTYRIC ACID; DEPSIPEPTIDE; FR 901228; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; PROTEIN TEL AML1; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; BONE MARROW CELL; CANCER RESISTANCE; CELL KILLING; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTINEOPLASTIC AGENTS; ASPARAGINASE; B-LYMPHOCYTES; BONE MARROW CELLS; BUTYRATES; CELL DIFFERENTIATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DEPSIPEPTIDES; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, PRE-B-CELL; MYELOID CELLS; ONCOGENE PROTEINS, FUSION; TUMOR CELLS, CULTURED;

EID: 29144509530     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-48.
2. Zelent A, Greaves M, Enver T. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene 2004;23:4275-83.
3. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D, et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:3262-8.
4. Stams WA, den Boer ML, Beverloo HB, Meijerink JP, Stigter RL, van Wering ER, et al. Sensitivity to L-asparaginase is not associated with expression levels or asparagine synthetase in t(12;21)+ pediatric ALL. Blood 2003;101:2743-7.
5. Ramakers-van Woerden NL, Pieters R, Loonen AH, Hubeek I, van Drunen E, Beverloo HB, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 2000;96:1094-9.
6. Stams WA, den Boer ML, Holleman A, Appel IM, Beverloo HB, van Wering ER, et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 2005;105:4223-5.
7. van Lochem EG, van der Velden VH, Wind HK, te Marvelde JG, Westerdaal NA, van Dongen JJ. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry 2004;60B:1-13.
8. Noordzij JG, de Bruin-Versteeg S, Verkaik NS, Vossen JM, de Groot R, Bernatowska E, et al The immunophenotypic and immunogenotypic B-cell differentiation arrest in bone marrow of RAG-deficient SCID patients corresponds to residual recombination activities of mutated RAG proteins. Blood 2002;100:2145-52.
9. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001;61:2-7.